Leerink Partnrs lowered shares of iTeos Therapeutics (NASDAQ:ITOS - Free Report) from a strong-buy rating to a hold rating in a research report report published on Wednesday morning,Zacks.com reports. Leerink Partnrs also issued estimates for iTeos Therapeutics' Q4 2025 earnings at ($0.38) EPS and FY2029 earnings at ($1.78) EPS.
A number of other analysts have also recently commented on ITOS. Wells Fargo & Company reiterated an "overweight" rating and issued a $13.00 target price (down from $16.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 14th. JPMorgan Chase & Co. cut iTeos Therapeutics from an "overweight" rating to a "neutral" rating and lowered their price target for the stock from $15.00 to $8.00 in a research report on Tuesday, May 13th. HC Wainwright lowered iTeos Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday, May 14th. Piper Sandler reaffirmed an "overweight" rating and set a $12.00 target price (down previously from $16.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Finally, Wedbush reiterated an "outperform" rating and issued a $25.00 target price on shares of iTeos Therapeutics in a research report on Wednesday, March 5th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $17.86.
Check Out Our Latest Research Report on iTeos Therapeutics
iTeos Therapeutics Price Performance
ITOS stock remained flat at $8.41 during trading on Wednesday. The company had a trading volume of 471,860 shares, compared to its average volume of 551,877. The company's 50 day moving average price is $6.63 and its 200 day moving average price is $7.40. iTeos Therapeutics has a 12 month low of $4.80 and a 12 month high of $18.70. The company has a market capitalization of $321.88 million, a P/E ratio of -2.67 and a beta of 1.39.
iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last released its quarterly earnings results on Monday, April 28th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.14. Equities research analysts expect that iTeos Therapeutics will post -3.49 earnings per share for the current fiscal year.
Insider Activity
In other news, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of iTeos Therapeutics stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total value of $5,079,339.46. Following the sale, the insider now directly owns 2,108,594 shares of the company's stock, valued at $16,995,267.64. The trade was a 23.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Ansbert Gadicke sold 1,031,931 shares of the business's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total value of $8,317,363.86. Following the sale, the insider now owns 3,452,797 shares of the company's stock, valued at $27,829,543.82. The trade was a 23.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 12.50% of the company's stock.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ITOS. SG Americas Securities LLC raised its position in shares of iTeos Therapeutics by 12.2% in the fourth quarter. SG Americas Securities LLC now owns 13,866 shares of the company's stock valued at $106,000 after buying an additional 1,508 shares during the last quarter. Wells Fargo & Company MN grew its stake in iTeos Therapeutics by 16.9% during the 4th quarter. Wells Fargo & Company MN now owns 16,644 shares of the company's stock valued at $128,000 after acquiring an additional 2,402 shares in the last quarter. Virtus ETF Advisers LLC grew its stake in iTeos Therapeutics by 58.2% during the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company's stock valued at $69,000 after acquiring an additional 3,293 shares in the last quarter. Empowered Funds LLC raised its holdings in iTeos Therapeutics by 5.0% in the 4th quarter. Empowered Funds LLC now owns 69,072 shares of the company's stock valued at $530,000 after acquiring an additional 3,305 shares during the last quarter. Finally, Bridgeway Capital Management LLC lifted its stake in iTeos Therapeutics by 5.0% in the 4th quarter. Bridgeway Capital Management LLC now owns 69,072 shares of the company's stock worth $530,000 after purchasing an additional 3,305 shares in the last quarter. Hedge funds and other institutional investors own 97.16% of the company's stock.
About iTeos Therapeutics
(
Get Free Report)
iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
See Also
Before you consider iTeos Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iTeos Therapeutics wasn't on the list.
While iTeos Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
